[Corrections] Correction to Lancet Oncol 2018; 19: 510–20

Maio M, Lewis K, Demidov L, et al. Adjuvant vemurafenib in resected, BRAFV600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial. Lancet Oncol 2018; 19: 510–20—In the Summary, Findings, in the second sentence, the p value should have read p=0·26. The appendix file has also been updated. These corrections have been made to the online version as of March 28, 2018, and the printed version is correct.

https://ift.tt/2pMPqA5